Cardiovascular Associates of America, which calls Orlando home, has made increasing its presence in the Sunshine State a top priority in 2023.

Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

ACC Vice President Cathleen Dalton Biga, MSN, RN, will serve as the group's next president. Cardiologist Christopher Kramer, MD, will be its next vice president. 

The FDA has categorized this as a Class I recall, meaning the use of these devices could cause “serious injuries or death.”

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

Overall, the recall includes 7,799 blood tests intended to help physicians identify early signs of a myocardial infarction. 

Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis. 

The new 44-page document focuses on the detection, classification and risk assessment of congenital heart issues.

CMS also floated the idea of pausing the AUC program until a better implementation strategy could be put into place. 

Versanis, founded in 2021 by a venture capital firm, is primarily known as the company behind the obesity drug bimagrumab.